基本信息
浏览量:85
职业迁徙
个人简介
I am an oncology drug development expert with more than 15 years of experience in the pharma industry supported by a strong academic track record (head of EORTC, first author on RECIST 1.0, > 100 peer reviewed papers). My areas of expertise extend from FIH to registration and life cycle management, for all tumor types (solid and liquid tumors) and a large panel of MOA/technology platforms including small molecules, monoclonal & bispecific antibodies, T-cell engagers; CART cell therapy and therapeutic cancer vaccines covering both cancer cell targeting and immune-oncology. I have experienced interacting with all major regulatory agencies across the globe and staff management in US and EU including research labs and early/late clinical drug development units. Along my pharma industry career, I have also been involved heavily in business development activities (in-licensing, out -licensing, acquisitions) and cross-functional strategic portfolio management within an oncology business unit (GSK) or company therapeutic area (Servier).
研究兴趣
论文共 82 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Clinical Cancer Researchno. 7 (2019): 1725-1735
The Lancet Oncologyno. 7 (2018): 916-929
The Lancet Oncologyno. 3 (2017): e143-e152
Seymour Lesley, Bogaerts Jan, Perrone Andrea, Ford Robert, Schwartz Lawrence H,Mandrekar Sumithra, Lin Nancy U, Litiere Saskia,Dancey Janet,Chen Alice, Hodi F Stephen,Therasse Patrick,
Lancet Oncologyno. 3 (2017): 143-152
引用0浏览0引用
0
0
The Lancet Oncologyno. 6 (2016): 822-835
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn